Ultra Market Research | United Kingdom Cardiomyopathy and Heart Failure Market
United Kingdom Cardiomyopathy and Heart Failure Market
Report ID : 1042
Category : United-Kingdom(UK)
No Of Pages : 154
Published on: March 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United Kingdom Cardiomyopathy and Heart Failure Market
Introduction
The United Kingdom Cardiomyopathy and Heart Failure Market is a fast-growing sector of the healthcare market. Cardiomyopathy is described as heart muscle diseases that disrupt its function of pumping blood adequately, whereas heart failure is observed when the heart is unable to provide the necessary circulatory support to the body. As a group, these conditions place an enormous burden on public health in the UK, with increasing prevalence as a result of aging populations and lifestyle choices. The market is expanding due to the growth in diagnostic methods, treatments, and insight into cardiovascular illness. Cardiomyopathy and heart failure management has seen dramatic changes with better drugs, medical devices, and continued investigation into new treatments. Trends are such that there is a significant rise in personalized medicine and advancements in heart transplantation, artificial hearts, and gene therapy. By 2024, the market size is anticipated to grow to £2.4 billion with a CAGR of 5.6% during the next five years as demand for improved treatment options keeps growing.
AstraZeneca (United Kingdom) Novartis (Switzerland) Pfizer (United States) Bayer (Germany) Abbott Laboratories (United States) Johnson & Johnson (United States) Merck & Co. (United States) Bristol-Myers Squibb (United States) Medtronic (Ireland) Boston Scientific (United States) Gilead Sciences (United States) Sanofi (France) GlaxoSmithKline (United Kingdom) Boehringer Ingelheim (Germany) Fresenius Medical Care (Germany)
Drivers
The expansion of the United Kingdom Cardiomyopathy and Heart Failure Market is driven by various major factors. The increasing incidence of cardiovascular diseases, i.e., heart failure and cardiomyopathy, resulting from aging populations and unhealthy lifestyle decisions, is one of the major drivers. There has been a substantial increase in demand for improved and superior treatment options, including personalized medicine, advanced medical devices, and novel drug therapies. Also, government funding for healthcare facilities and growing concern regarding the treatment of heart diseases are driving growth in the market. Growth of heart transplantation and ventricular support devices is additionally supporting treatment methods for advanced diseases. Further, diagnostic advancements through genetic testing and imaging technologies are facilitating early identification and treatment, which enhances outcomes for patients as well as aiding market growth.
Restraints
Even though the United Kingdom Cardiomyopathy and Heart Failure Market is expanding, there are a number of challenges facing it. The expense of new treatments and medical equipment, like heart transplants and LVADs, can be a problem, particularly in public healthcare systems with restrictions in budgets. Second, the multifactorial nature of cardiomyopathy and heart failure ensures that there are patients who do not react to standard treatments, necessitating more individualized and expensive interventions. The lack of donors for heart transplant is another important limiting factor, restricting the availability of treatments. Additionally, the regulatory barriers to approval of novel drugs and devices may retard entry into the market, reducing therapy options for desperate patients. Last, the inadequacy of qualified healthcare professionals for advanced cardiology procedures would restrict the market's full potential.
Opportunity
The United Kingdom Cardiomyopathy and Heart Failure Market offers many opportunities for growth. Advances in technology, including gene therapy, artificial hearts, and stem cell studies, are of great potential to revolutionize treatment modalities. The growing emphasis on precision medicine, which personalizes treatments to unique genetic profiles, is also a significant area of development. In addition, the increasing focus on telemedicine and remote monitoring systems may extend patient access to care, particularly for those who are in rural areas or have mobility issues. There is also a significant opportunity for firms to create low-cost treatments and medical devices that can target the cost pressures of the healthcare system. Finally, continued clinical trials and research programs aimed at optimizing heart failure outcomes will provide new opportunities for innovation and treatment strategies.
Trend
Among the current trends within the United Kingdom Cardiomyopathy and Heart Failure Market is increasing demand for minimally invasive techniques. Health providers and patients are turning away from traditional forms of surgery to take advantage of quicker recovery time and fewer complications that less invasive options such as robot-assisted and catheter-based procedures can provide. Moreover, there is a trend noticed in the utilization of wearable devices for persistent monitoring of heart conditions for real-time tracking of data and early complications detection. Another prevailing trend is the expansion of regenerative medicine, such as stem cell therapies and tissue engineering, that holds potential in repairing or regenerating injured heart tissue. This strategy may significantly influence treatment outcomes and enhance quality of life for patients with advanced heart disease.
Entresto (Sacubitril/Valsartan) Farxiga (Dapagliflozin) Ivabradine (Corlanor) Verquvo (Vericiguat) Jardiance (Empagliflozin) Medtronic MiniMed 670G Insulin Pump Impella Heart Pump HeartWare HVAD System CardioMEMS Heart Failure Monitoring System Biomarker-based cardiac monitoring devices
Key Target Audience
Hospitals and healthcare providers Cardiology clinics Research institutions Pharmaceutical companies Medical device manufacturers Regulatory bodies and government agencies Biotechnology firms Heart failure and cardiomyopathy patients Health insurance companies Medical equipment distributors
The market is valued at approximately £2.4 billion in 2024 and is expected to grow at a CAGR of 5.6% over the next five years.
Key drivers include the rising prevalence of heart failure, advancements in treatment options, government investments, and increased public awareness.
Common treatments include medications like ACE inhibitors and beta-blockers, surgical procedures like heart transplants, and medical devices such as LVADs and pacemakers.
High treatment costs, limited organ donors, and regulatory challenges are major constraints affecting market growth.
Opportunities include the development of gene therapies, personalized medicine, telemedicine solutions, and affordable medical devices to meet patient needs.
1. Introduction
1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview
3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Treatment Types 3.2.1.1 Chemotherapy - Induction Phase - Consolidation Phase - Maintenance Phase 3.2.1.2 Targeted Therapies - Tyrosine Kinase Inhibitors - Antibody-Drug Conjugates - Others 3.2.1.3 Immunotherapies - CAR-T Therapy - Monoclonal Antibodies 3.2.2 By Patient Demographics 3.2.2.1 Children - Infants - Toddlers and Young Children 3.2.2.2 Adults - Young Adults - Seniors 3.2.3 By Distribution Channels 3.2.3.1 Hospital Pharmacies - Tertiary Care Centers - Pediatric Cardiology Units 3.2.3.2 Retail Pharmacies - Local Pharmacies - Chain Pharmacies 3.2.3.3 Online Pharmacies 3.2.4 By Therapeutic Applications 3.2.4.1 First-Line Treatment - Chemotherapy-Only Regimens - Targeted Therapies 3.2.4.2 Relapse or Refractory Cardiomyopathy and Heart Failure - CAR-T Therapies - Experimental Treatments
5. United Kingdom Cardiomyopathy and Heart Failure Market by Patient Demographics
5.1 Introduction 5.2 Market Size and Growth Rate by Patient Demographics (2024-2030) 5.2.1 Children - Infants - Toddlers and Young Children 5.2.2 Adults - Young Adults - Seniors
6. United Kingdom Cardiomyopathy and Heart Failure Market by Distribution Channels
6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channels (2024-2030) 6.2.1 Hospital Pharmacies - Tertiary Care Centers - Pediatric Cardiology Units 6.2.2 Retail Pharmacies - Local Pharmacies - Chain Pharmacies 6.2.3 Online Pharmacies
7. United Kingdom Cardiomyopathy and Heart Failure Market by Therapeutic Applications
7.1 Introduction 7.2 Market Size and Growth Rate by Therapeutic Applications (2024-2030) 7.2.1 First-Line Treatment - Chemotherapy-Only Regimens - Targeted Therapies 7.2.2 Relapse or Refractory Cardiomyopathy and Heart Failure - CAR-T Therapies - Experimental Treatments
Table United Kingdom Cardiomyopathy and Heart Failure Market Size by Treatment Types (2024-2030) Table Chemotherapy Market Size by Sub-type (2024-2030) Table Targeted Therapies Market Size by Sub-type (2024-2030) Table Immunotherapies Market Size by Sub-type (2024-2030) Table United Kingdom Cardiomyopathy and Heart Failure Market Size by Patient Demographics (2024-2030) Table Children Market Size by Sub-type (2024-2030) Table Adults Market Size by Sub-type (2024-2030) Table United Kingdom Cardiomyopathy and Heart Failure Market Size by Distribution Channels (2024-2030) Table Hospital Pharmacies Market Size by Sub-type (2024-2030) Table Retail Pharmacies Market Size by Sub-type (2024-2030) Table United Kingdom Cardiomyopathy and Heart Failure Market Size by Therapeutic Applications (2024-2030) Table First-Line Treatment Market Size by Sub-type (2024-2030) Table Relapse or Refractory Cardiomyopathy and Heart Failure Market Size by Sub-type (2024-2030)
10.2 List of Figures
Figure United Kingdom Cardiomyopathy and Heart Failure Market Size and Growth Rate by Treatment Types (2024-2030) Figure Chemotherapy Market Growth Rate by Sub-type (2024-2030) Figure Targeted Therapies Market Growth Rate by Sub-type (2024-2030) Figure Immunotherapies Market Growth Rate by Sub-type (2024-2030) Figure United Kingdom Cardiomyopathy and Heart Failure Market Size and Growth Rate by Patient Demographics (2024-2030) Figure Children Market Growth Rate by Sub-type (2024-2030) Figure Adults Market Growth Rate by Sub-type (2024-2030) Figure United Kingdom Cardiomyopathy and Heart Failure Market Size and Growth Rate by Distribution Channels (2024-2030) Figure Hospital Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Retail Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure United Kingdom Cardiomyopathy and Heart Failure Market Size and Growth Rate by Therapeutic Applications (2024-2030)
10.3 Financial Overview of Key Companies
Table Amgen Inc. Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Novartis AG Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Pfizer Inc. Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Gilead Sciences Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Kite Pharma Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Takeda Pharmaceutical Company Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Bristol-Myers Squibb Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Jazz Pharmaceuticals Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table AbbVie Inc. Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Sanofi Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Autolus Therapeutics Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Cellectis Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Allogene Therapeutics Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Celgene Corporation Cardiomyopathy and Heart Failure Therapeutic Financial Overview Table Eli Lilly and Company Cardiomyopathy and Heart Failure Therapeutic Financial Overview
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United States market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States Molluscum Contagiosum Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United States Molluscum Contagiosum Market for the past year and forecasts for the next six years. United States Molluscum Contagiosum Market size is given in terms of revenue Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Molluscum Contagiosum Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United States Molluscum Contagiosum Market from different application industries in different regions.
